Jasper Therapeutics Inc (JSPR) Stock AnalysisJSPRStock AnalysisJasper Therapeutics Inc

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Jasper Therapeutics Inc is currently not a strong buy due to its low current price of $0.6997, significant losses, and mixed analyst ratings. The RSI is at 38.806, indicating potential oversold conditions, but the stock has a high price-to-book ratio of 16.47, suggesting overvaluation. The main risk is the company's cash burn rate, which is unsustainable given its current cash reserves of $7.3 million against a burn rate of approximately $11 million per quarter, indicating potential liquidity issues.